Eli Lilly and Company (NYSE: LLY) recently announced promising results from its SUMMIT phase 3 trials, focusing on the efficacy of the tirzepatide injection. The positive findings have sparked ...

Eli Lilly has benefitted from the windfall from tirzepatide – the active ingredient in its weight loss injection Zepbound and diabetes shot Mounjaro – which targets GLP-1 but also activates ...

Eli Lilly also raised its full-year adjusted earnings to a range between $16.10 to $16.60, up from its previous guidance of $13.50 to $14 per share. Eli Lilly’s results suggest its leadership in ...

Why It Matters: In a motion filed on New Year, Eli Lilly said it seeks to intervene to protect its interests and help bring this suit to a swift end. Eli Lilly says, “Plaintiffs seek to reverse ...

Eli Lilly & Co. Inc.’s stock rose 2.7% Thursday, after the drug company said its tirzepatide treatment for Type 2 diabetes and weight loss achieved positive results in a late-stage trial ...

Amid unprecedented demand for Eli Lilly’s injection, the NHS proposes that those with a body mass index of more than 40 kg/m2 who also have at least three comorbidities of hypertension, ...

Eli Lilly said its daily obesity pill met the company's goals in the first of several closely watched late-stage trials. The pill helped Type 2 diabetes patients lower their blood sugar and body ...

The level of weight loss was similar to that achieved over the same period with Novo Nordisk’s injection but slightly lower than that with Eli Lilly’s injection in unrelated trials.